Best Oncology Companies in Taiwan

Developer of precision cancer therapeutics. It offers drug candidates ABT-101 a tyrosine kinase inhibitor targeting HER2 Exon20 insertion from solid tumor cancer, ABT-201 a KRAS inhibitor targeting non-small cell lung cancer, and ABT-301 a small molecule histone deacetylase inhibitor (HDACi).

Funding rounds

• Jan 2024Series A$12.5M

Founders & team

Tsu-An HsuFounder & CEO

Investors

CDIB Capital Group, Maxpro Ventures, Taian Biotechnology, National Development Council

Tech stack

BootstrapCloudflareCloudflare Browser InsightsCodeigniterGoogle AnalyticsGoogle Font Api

Developer of therapeutics for cancer, neurology, and age-related diseases. It offers protein degradation drugs which include AH-001 for the treatment of androgenetic alopecia. It also provides drugs for prostate cancer, lymphoma, pancreatic, and colorectal cancer, neurodegenerative disease, and others.

Funding rounds

• Apr 2023Series A$10M

Founders & team

Chu-Chiang LinChief Executive Officer

Investors

Taiwania Capital, ITRI, Hongtai Electric, Sunplus, Blackmarble, Mega Financial Holding

Tech stack

AstraCdnjsCloudflareCloudflare Browser InsightsCore-JsElementor

Developer of immunotherapy for cancer and immunological diseases. The company's drug candidates include EI-1071 for Alzheimer's disease, tenosynovial giant cell tumors, EI-001 for vitiligo, and others for cancer. The platform has developed the proprietary human single B cell cloning technology and anti-cytokine monoclonal antibodies for targeting the immunosuppressive tumor for cancer treatment.

Funding rounds

• Jul 2022Grant (prize money)—
• Aug 2021Series A$27M
• Aug 2020Grant (prize money)$1M

Founders & team

DawTsun ShihCo-Founder & CSOHungKai ChenCo-Founder & CEOMuhHwa YangCo-Founder

Investors

Alzheimer’s Association, Grains Valley Venture Capital, CDIB Capital, Fubon Financial Holdings, Mega International Commercial Bank, Taiwania Capital

Tech stack

Apache Http ServerAxiosFancyboxHstsIisJquery

Foresee Pharmaceuticals develops injectables and NCEs for cancer, endocrine disorders, and inflammatory diseases. Its stabilized injectable formulation platform is primarily a controlled release drug delivery platform for small molecules, peptides, and other bioactive. Its lead candidate is in phase III trials for prostate cancer, and another candidate in phase II trials for COPD and asthma. In addition, it has other candidates for acromegaly, opioid dependence, diabetic retinopathy and alport syndrome in preclinical studies. Its pipeline candidates are FP-001 (Leuprolide) for prostate cancer, FP-004 (Buprenorphine) for opioid dependence, and FP-011 (Goserelin) for the breast cancer among others.

ACT Genomics offers clinical and research services in genomics for cancer. Its clinical offerings include NGS panels for auto-immune disease (ACTImmune), colon cancer (ACTColon), gastric cancer (ACTGastric) and breast cancer (ACTBreast). It also provides pharmacogenomic panels ACTDrug and ACTOnco that help physicians tailor therapies according to the patient's genotype. In addition, the company provides custom genomic services for biopharma companies and research institutions.

Funding rounds

• Sep 2020Series B—
• Sep 2018Series B—
• May 2016Series B$12.5M
• Feb 2015Series A$8M

Founders & team

Shu ChenCo-Founder & CSO

Investors

Kyoto University Innovation Capital, Aflac Innovation Partners, Hotung Investment Holdings, President International Development Corp, UMC Capital, Hua Nan Financial Holdings

Tech stack

CloudflareCore-JsFacebook PixelGoogle AnalyticsGoogle Font ApiGoogle Hosted Libraries

Senhwa Biosciences is developing small molecules for treating cancer. The lead candidate of the company is CX-5461, which is a synthetically derived small molecule and a G-quadruplexes (G4) stabilizing compound. It is being investigated for treating breast cancer. The candidate has completed phase II clinical trials. CX-4945 is also going to phase II trials.

Developer of OCT-based medical imaging devices. It designs and develops optical coherence tomography (OCT) technology, which helps to generate high-resolution 2D and 3D images in a non-destructive, preparation-free manner. Its product is a bench-top full-field optical coherence tomography (FF-OCT) system for non-invasive medical examination providing cellular level images of excised tissues or cultured cells. The products of the company have use cases in multiple applications, including tumor detection, and medical cosmetic testing.

Synermore Biologics is focused on research and development of new and biosimilar monoclonal antibodies in the areas of oncology, infectious diseases, and immune disorders. Its core competence is to bring products from research stage through IND-enabling nonclinical and CMC activities to clinical stage of development. Its lead product SYN004, a monoclonal antibody that binds to the EGF receptor and inhibits the cancer cells is in phase 1 trials. Its other new MAbs SYN023 & SYN098 for infectious diseases are in pre-clinical trials. Additionally, it also has four biosimilars in different phases for immune disorder, oncology, autoimmune disease and bone metabolism.

TaiRx was founded under the strategic alliance of Formosa Laboratories and Efficient Pharma Management Corp. to develop a new generation of novel NCE for cancer treatment. In 2013, TaiRx started a series of financing and expanded their product pipeline. In addition to cancer treatment, they have expanded their reach to other major diseases. Several products are under development and entering clinical trials to ensure their safety and efficacy. Their pipeline currently has the following drugs: CVM-1118, a small molecule vasculogenic mimicry (VM) inhibitor to treat cancer undergoing Phase I studies; Rexis, an add-on injection therapy for patients with sepsis; and TRX-606, a novel formulation platform to enhance the drug absorption by changing it from the original injection form into an oral form.